NasdaqGS - Nasdaq Real Time Price USD

Alnylam Pharmaceuticals, Inc. (ALNY)

307.99

+3.32

+(1.09%)

At close: 4:00:02 PM EDT

306.63

-1.36

(-0.44%)

After hours: 4:57:12 PM EDT

The European Commission Approves Alnylam’s AMVUTTRA

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9, 2025, that AMVUTTRA® (vutrisiran) has been approved by the European Commission to treat wild-type or hereditary ATTR amyloidosis with cardiomyopathy (ATTR-CM). As a result, AMVUTTRA is the first and only RNAi treatment approved in the […]

Insider Monkey yesterday

ALNY
+1.09%
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instil’s wholly-owned subsidiary dedicated to the development of AXN-2510 (“’2510”), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCL

GlobeNewswire 2 days ago

TIL

ALNY
+1.09%
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Zacks 3 days ago

ALNY
+1.09%
EC approves Alnylam’s vutrisiran for ATTR-CM treatment

The approval is grounded on the positive HELIOS-B Phase III trial outcomes.

Pharmaceutical Technology 3 days ago

ALNY
+1.09%
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., June 09, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and only R

Business Wire 4 days ago

ALNY
+1.09%
Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 8 days ago

SRPT

ALNY
+1.09%
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 am ET.

Business Wire 16 days ago

ALNY
+1.09%
3 High-Flying Stocks That Could Soar Even More

Alnylam Pharmaceuticals has had a lot of excitement this year, with more good news potentially on the way. Summit Therapeutics could keep its momentum going with positive clinical results for cancer drug ivonescimab. Here's why they picked Alnylam Pharmaceuticals (NASDAQ: ALNY), Axsome Therapeutics (NASDAQ: AXSM), and Summit Therapeutics (NASDAQ: SMMT).

Motley Fool 20 days ago

ALNY
+1.09%

AXSM

SMMT
Alnylam Issues 2024 Corporate Responsibility Report

CAMBRIDGE, Mass., May 20, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Guided by the theme of "Accepting Challenges to Improve the Health of Humanity," Alnylam continues to take meaningful steps across each of its six corporate responsibility pillars. This year’s edition highlights the company’s progress, data, and stories demonstrating its commitment to patient access, an a

Business Wire 24 days ago

ALNY
+1.09%
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

CAMBRIDGE, Mass., May 17, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The results demonstrate that vutrisiran, which rapidly

Business Wire 27 days ago

ALNY
+1.09%
High Growth US Tech Stocks To Watch In May 2025

The United States market has shown robust performance with a 4.5% rise over the last week and an 11% increase in the past year, supported by an anticipated annual earnings growth of 14%. In this favorable environment, identifying high growth tech stocks that align with these positive trends can be key to capitalizing on potential opportunities.

Simply Wall St. 28 days ago

ALNY
+1.09%

PANW

NFLX
Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term

We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, […]

Insider Monkey 30 days ago

ALNY
+1.09%
Alnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure Congress

In May 2025, Alnylam Pharmaceuticals (NasdaqGS:ALNY) announced its plan to present new data from its transthyretin amyloidosis (TTR) franchise at the Heart Failure 2025 Congress, alongside securing broader international approvals for its therapeutic vutrisiran (AMVUTTRA). During the same month, the overall market rallied due to positive developments in U.S.-China trade relations, with major indexes experiencing substantial gains. Alnylam's 5.63% rise over the period likely reflects investor...

Simply Wall St. last month

ALNY
+1.09%
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) is possibly approaching a major achievement in its business, so we would...

Simply Wall St. last month

ALNY
+1.09%
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock

Many Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) insiders ditched their stock over the past year, which may be of...

Simply Wall St. last month

ALNY
+1.09%
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.

Pharma Voice last month

ALNY
+1.09%

PFE
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Despite a significant revenue drop, Vir Biotechnology Inc (VIR) maintains a strong cash position and progresses in key therapeutic areas.

GuruFocus.com last month

VIR

ALNY
+1.09%
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

CAMBRIDGE, Mass., May 05, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET).

Business Wire last month

ALNY
+1.09%
Analyst Estimates: Here's What Brokers Think Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its First-Quarter Report

Investors in Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) had a good week, as its shares rose 3.1% to close at US$259...

Simply Wall St. last month

ALNY
+1.09%
Alnylam Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Alnylam Pharmaceuticals ( NASDAQ:ALNY ) First Quarter 2025 Results Key Financial Results Revenue: US$594.2m (up 20...

Simply Wall St. last month

ALNY
+1.09%

Performance Overview

Return	ALNY	S&P 500 (^GSPC)
YTD	+30.89%	+1.62%
1-Year	+92.43%	+10.00%
3-Year	+141.18%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alnylam Pharmaceuticals, Inc. (ALNY)

The European Commission Approves Alnylam’s AMVUTTRA

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM

EC approves Alnylam’s vutrisiran for ATTR-CM treatment

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

3 High-Flying Stocks That Could Soar Even More

Alnylam Issues 2024 Corporate Responsibility Report

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

High Growth US Tech Stocks To Watch In May 2025

Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term

Alnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure Congress

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability

Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock

Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

Analyst Estimates: Here's What Brokers Think Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its First-Quarter Report

Alnylam Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Performance Overview